Firebrick Pharma Management
Management criteria checks 4/4
Firebrick Pharma's CEO is Peter Molloy, appointed in Apr 2012, has a tenure of 13.25 years. total yearly compensation is A$296.14K, comprised of 95.8% salary and 4.2% bonuses, including company stock and options. directly owns 14.16% of the company’s shares, worth A$1.97M. The average tenure of the management team and the board of directors is 4.6 years and 13.3 years respectively.
Key information
Peter Molloy
Chief executive officer
AU$296.1k
Total compensation
| CEO salary percentage | 95.76% |
| CEO tenure | 13.3yrs |
| CEO ownership | 14.2% |
| Management average tenure | 4.6yrs |
| Board average tenure | 13.3yrs |
Recent management updates
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14
We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -AU$2m |
| Sep 30 2024 | n/a | n/a | -AU$1m |
| Jun 30 2024 | AU$296k | AU$284k | -AU$1m |
| Mar 31 2024 | n/a | n/a | -AU$3m |
| Dec 31 2023 | n/a | n/a | -AU$5m |
| Sep 30 2023 | n/a | n/a | -AU$6m |
| Jun 30 2023 | AU$351k | AU$284k | -AU$7m |
| Mar 31 2023 | n/a | n/a | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$5m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | AU$324k | AU$252k | -AU$4m |
| Mar 31 2022 | n/a | n/a | -AU$3m |
| Dec 31 2021 | n/a | n/a | -AU$3m |
| Sep 30 2021 | n/a | n/a | -AU$3m |
| Jun 30 2021 | AU$140k | AU$140k | -AU$2m |
Compensation vs Market: Peter's total compensation ($USD192.71K) is below average for companies of similar size in the Australian market ($USD290.89K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Molloy (71 yo)
Dr. Peter Laurence Molloy, BSc, MBA, FAICD is the Founder, Executive Chairman and Chief Executive Officer of Firebrick Pharma Limited since April 12, 2012. He served as Managing Director and Chief Executiv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.3yrs | AU$296.14k | 14.16% A$ 2.0m | |
| Founder | 13.3yrs | AU$250.09k | 13.82% A$ 1.9m | |
| Chief Financial Officer | 2.6yrs | no data | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Head of Regulatory Affairs | 3.6yrs | no data | no data | |
| Company Secretary | 4.6yrs | no data | no data |
Experienced Management: FRE's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.3yrs | AU$296.14k | 14.16% A$ 2.0m | |
| Founder | 13.3yrs | AU$250.09k | 13.82% A$ 1.9m | |
| Independent Non-Executive Director | 4.7yrs | AU$60.00k | 0.27% A$ 37.2k |
Experienced Board: FRE's board of directors are seasoned and experienced ( 13.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/19 17:16 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Firebrick Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.